Compare INFQ & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFQ | ZLAB |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | China |
| Employees | 205 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2026 | 2017 |
| Metric | INFQ | ZLAB |
|---|---|---|
| Price | $12.50 | $20.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $20.00 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 10.3M | 623.7K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $25.46 | $9.75 |
| Revenue Next Year | $25.00 | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $8.52 | $15.96 |
| 52 Week High | $21.28 | $44.34 |
| Indicator | INFQ | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 49.20 |
| Support Level | $10.98 | $16.88 |
| Resistance Level | $13.70 | $25.28 |
| Average True Range (ATR) | 1.06 | 1.03 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 36.10 | 56.48 |
Infleqtion Inc developing and commercializing quantum technology products as part of a full-stack platform, which currently includes offerings such as quantum sensing, quantum computing, and software. Its quantum-enabled solutions are focused on addressing the world's pressing challenges, with technologies actively deployed across some sectors today, including defense and security, artificial intelligence (AI), energy optimization, space and frontier, materials discovery, and cybersecurity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.